1	State of Arkansas	A Bill	
2	95th General Assembly Regular Session, 2025	ADIII	HOUSE BILL 1055
3 4	Regular Session, 2023		HOUSE BILL 1055
5	By: Representatives J. Mayber	ry, Rye, Breaux, Springer	
6	By: Senators C. Penzo, F. Lov		
7			
8		For An Act To Be Entitled	
9	AN ACT TO ESTABLISH COVERAGE DIAGNOSIS AND TREATMENT		
10	TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE OR		
11	OTHER DEMENTIA-RELATED DISEASE UNDER THE STATE AND		
12	PUBLIC SCHOOL LIFE AND HEALTH INSURANCE PROGRAM; AND		
13	FOR OTHER	PURPOSES.	
14			
15			
16		Subtitle	
17	TO ES	TABLISH COVERAGE DIAGNOSIS AND	
18	TREAT	MENT TO SLOW THE PROGRESSION OF	
19	ALZHE	IMER'S DISEASE OR OTHER DEMENTIA-	
20	RELAT	ED DISEASE UNDER THE STATE AND	
21	PUBLI	C SCHOOL LIFE AND HEALTH INSURANCE	
22	PROGR	AM.	
23			
24	BE IT ENACTED BY THE G	ENERAL ASSEMBLY OF THE STATE OF ARKANS	SAS:
25			
26	SECTION 1. Arkan	nsas Code Title 21, Chapter 5, Subchap	oter 4, is amended
27	to add an additional so	ection to read as follows:	
28	<u>21-5-425.</u> Covera	age for diagnosis and treatment of Alz	heimer's disease
29	<u>or other dementia-rela</u>	<u>ted disease — Legislative findings and</u>	l intent — Rules.
30	<u>(a)</u> The General	Assembly finds that:	
31	(1) Alzhe:	imer's disease is the seventh leading	<u>cause of death in</u>
32	Arkansas according to	the Centers for Disease Control and Pr	evention;
33	<u>(2)</u> The co	ost of managing the complications of l	<u>ate-stage</u>
34	<u>Alzheimer's disease, la</u>	argely due to delayed diagnosis and ac	<u>cess to</u>
35	<u>treatment</u> , outweighs tl	he cost of expeditious and effective t	reatment;
36	<u>(3)</u> The d	iagnosis and treatment of Alzheimer's	<u>disease or other</u>



1	dementia-related disease should be a clinical decision made by a physician		
2	based on evidence-based guidelines; and		
3	(4) The United States Food and Drug Administration has granted		
4	approval for treatments of patients in the early stages of Alzheimer's		
5	disease.		
6	(b) It is the intent of the General Assembly to provide coverage for		
7	the diagnosis and treatment of Alzheimer's disease or other dementia-related		
8	disease.		
9	(c) Each state employee's and public school employee's health benefit		
10	plan under the State and Public School Life and Health Insurance Program that		
11	is offered, issued, or renewed on or after January 1, 2026, shall offer		
12	coverage for the diagnosis and treatment of Alzheimer's disease or other		
13	dementia-related disease as determined by a physician licensed to practice		
14	medicine in this state.		
15	(d) The coverage and treatment of Alzheimer's disease or other		
16	dementia-related disease offered under subsection (c) of this section shall:		
17	(1) Be a treatment or medication that has been approved by the		
18	United States Food and Drug Administration to treat or slow the progression		
19	of Alzheimer's disease or other dementia-related disease;		
20	(2) Include without limitation:		
21	(A) Any diagnostic testing that is necessary for a		
22	physician to determine the appropriate use of treatments and medications		
23	under subdivision (d)(l) of this section; and		
24	(B) All treatments or medications prescribed to slow the		
25	progression of Alzheimer's disease or other dementia-related disease; and		
26	(3) Not be subject to step therapy protocols.		
27	(e) The State Board of Finance may promulgate rules to implement this		
28	section.		
29			
30			
31			
32			
33			
34			
35			
36			